- FDA approves Plan B One-Step OTC switch
- Senate passes Drug Quality and Security Act
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Eat Well, Test Well: Bayer HealthCare and dLife Healthcare Solutions launch diabetes resource
- Study: Type 2 diabetes market competition heats up amid disease rate increase
BASEL, Switzerland — Roche has received approval from the Food and Drug Administration for its new generation of blood-glucose test strips.
Roche said that its Accu-Chek Aviva Plus test strips are maltose-independent test strips that are designed to prevent the interference of maltose on blood-sugar readings, which can occur in rare cases when drugs containing or metabolizing to maltose are parenterally administered.
The Accu-Chek Aviva Plus test strip is cleared for patient self-monitoring of blood glucose and can be used with the Accu-Chek Aviva system.
“We are very pleased to announce that our new product for self-monitoring of blood glucose will also be available for people with diabetes in the U.S.,” Roche Diagnostics COO Daniel O’ Day said. “With its advanced technology and chemistry it is designed to support patients to manage their condition more effectively. This clearance is a significant milestone for our organization — one that will position us well for the clearance of other products in our pipeline.”